D 1 Pd L1 Inhibitors Did Not Bring Satisfiedresponse Rate When Used As Monotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SUZHOU, China, June 14, 2022 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK)announced thatthe first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052, its proprietary PD-L1/OX40 bispecific antibody, in patients with advanced solid tumors in China. With the development of immunotherapy and further understanding of tumor pathogenesis, cancer therapy has entered a new era, among which PD-(L)1 inhibitors have become a star product. However, PD-1/PD-L1 inhibitors did not bring satisfiedresponse rate when used as monotherapy, and innovative treatment regimens are expected.KN052 is the world's first PD-L1/OX40 bispecific antibody entering first-in-human clinical study. It can effectively reverse tumor induced immune inhibition by blocking the PD-L1/PD-1 pathway and promote the immune response by activating OX40. In preclinical studies, KN052 showed significantly stronger activity than either single antibody or in combination. KN052-CHN-001 is a Phase I clinical ....

United States , Hong Kong , Hong Kong Stock Exchange , European Union , Chinese National Medical Products Administration , National Medical Products Administration , Zhengbo Song , Zhejiang Cancer Hospital , June 14 , 022 Prnewswire Alphamab Oncology Stock Code 9966 Hk Announced Thatthe First Patient Was Dosed Ina Phasei Clinical Study Kn052 Chn 001 Of , Ts Proprietary Pd L1 Ox40 Bispecific Antibody , N Patients With Advanced Solid Tumors In China The Development Of Immunotherapy And Further Understanding Tumor Pathogenesis , Ancer Therapy Has Entereda New Era , Mong Which Pdl 1 Inhibitors Have Becomea Star Product However , D 1 Pd L1 Inhibitors Did Not Bring Satisfiedresponse Rate When Used As Monotherapy , Nd Innovative Treatment Regimens Are Expected Kn052 Is The World 39s First Pd L1 Ox40 Bispecific Antibody Entering In Human Clinical Study It Can Effectively Reverse Tumor Induced Immune Inhibition By Blocking 1 Pathway And Promote Response Activating Preclinical Studies , N052 Showed Significantly Stronger Activity Than Either Single Antibody Or In Combination Kn052 Chn 001 Isa Phasei Clinical Study Chinese Patients With Advanced Solid Tumors To Evaluate The Safety , Harmacokinetics And Anti Tumor Activity Of Kn052 , Nd To Determine The Recommended Dose For Further Development Professor Zhengbo Song From Zhejiang Cancer Hospital , He Principal Investigator , Uot Ox40 Isa Member Of The Tnf Receptor Superfamily Mechanism Action Agonism Can Result In Conditions Favorable To Immune Responses , Here Activatedt Cells Increase In Number , Hile The Induction Of Tregs Is Suppressed In Periphery Combination Ox40 And An Immune Checkpoint Inhibitor Expected To Enhance Efficacy We Look Forward Exploring Safety Preliminary Kn052 This Clinical Study Quot About Isa Pd L1 Bispecific Antibody Developed House By Alphamab Oncology It Can Simultaneously Bind , Ffectively Blocking The Pd L1 1 Pathway And Activating Ox40 In February 2022 , He Ind For Kn052 Was Approved By The National Medical Products Administration Nmpa To Initiate Phasei Clinical Trials In China About Alphamab Oncology Is Focusing On Innovation , Ncluding Discovery ,